Introduction: Thymoma and thymic carcinoma (TC) are neoplastic diseases with reported chemosensitivity to a broad range of agents. However, because of the rarity of these diseases, few prospective trials have been conducted in patients with advanced thymic malignancies. We conducted a prospective phase II trial to evaluate the clinical activity of pemetrexed, a multitargeted antifolate agent, in previously treated patients with thymoma and TC.
Introduction
Thymic malignancies are rare neoplasms, with a reported incidence of 0.15 cases per 100,000. 1 They are the most common tumors presenting in the anterior mediastinum and account for 50% of such neoplasms in adults. 2, 3 Thymic carcinoma (TC) represents a more malignant phenotype of thymic tumors, typically presenting with a more aggressive clinical course. Surgical resection remains the mainstay of treatment for patients with localized thymic *Corresponding author.
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malignancies, whereas radiation and systemic chemotherapy are used for unresectable or metastatic disease. In patients with recurrent disease, additional chemotherapy is used for those deemed inoperable. Platinum-based regimens have demonstrated significant response rates and improved survival for such patients, but in relapsed disease, no established standard of care exists.
Multiple chemotherapy drugs are active in thymic malignancies, and the relatively indolent nature of this disease makes it a good candidate for exploring singleagent activity of new therapies in the relapse setting. Pemetrexed (Alimta, Eli Lilly and Company, Indianapolis, IN) is a multitargeted antifolate agent with demonstrated activity in a variety of malignancies. 4 Importantly, pemetrexed has significant activity alone or in combination in patients with other intrathoracic tumors, including malignant mesothelioma and NSCLC. [5] [6] [7] [8] At the time this trial was conceptualized, it was clinically rational to investigate pemetrexed in patients with relapsed thymic malignancies. We therefore conducted a phase II trial (ClinicalTrials.gov identifier NCT00198133) to evaluate the clinical activity of pemetrexed in patients with recurrent or metastatic thymoma and TC who relapsed after systemic therapy. We present survival outcomes of patients enrolled in this trial.
Patients and Methods
Patients with histologically confirmed invasive, surgically incurable, metastatic/advanced thymoma or TC that had progressed after initial systemic chemotherapy were eligible for this study. An original biopsy of the tumor was deemed sufficient for diagnosis and inclusion in the trial; patients were not stratified by histologic subtype, although eligible patients were required to have measurable disease on standard radiologic imaging obtained within 6 weeks before registration in the study. There was no limit to the number of prior treatments. Further eligibility criteria included adequate hepatic function (serum bilirubin level 1.5 mg/dL), renal function (calculated creatinine clearance level 45 mL/min by the CockcroftGault method), and an Eastern Cooperative Oncology Group performance status (PS) of 0 or 1 before entry. Hematologic requirements were a granulocyte count of 1500/mm 3 or higher and a platelet count of 100,000/mm 3 or higher. Patients were at least 18 years of age at the time of entry or allowed in with consent of their parent or legal guardian. Patients receiving a stable dose of corticosteroid for the treatment of myasthenia gravis were permitted to participate in the trial, whereas those with acute intercurrent complications, such as infection or inadequate postsurgical wound healing were deemed ineligible. Patients with known hypersensitivity to pemetrexed or any component of the product were not eligible for the study. Because of its potential teratogenicity, patients who were pregnant or nursing were excluded from study. For similar reasons, patients of reproductive age and capacity were permitted in the study with their commitment to adhere to strict contraceptive practices while receiving pemetrexed during the trial. Treatment with other nonapproved or investigational agents within 30 days before enrollment disqualified a patient from this study. The presence of clinically relevant third-space fluid collections not amenable to drainage (including but not limited to ascites or pleural effusions) and inability to interrupt aspirin or other nonsteroidal anti-inflammatory drugs for a 5-day period also excluded patients from the study. All patients were provided with a full study description and information and were to sign a written informed consent form before the initiation of treatment. The study was conducted in accordance with the ethical principles of the Declaration of Helsinki.
Treatment Procedures
All eligible patients were treated with pemetrexed, 500 mg/m 2 , as a 10-minute intravenous infusion once every 21 days, for a preplanned maximum of six cycles, disease progression, or undue toxicity, whichever occurred first. All patients were pretreated with vitamin B 12 , 1000 mg, given as an intramuscular injection 1 to 2 weeks before the first dose of pemetrexed; the injection was repeated approximately every 9 weeks until 3 weeks after the last treatment dose. Similarly, all patients received folic acid supplementation (350-1000 mg) given orally beginning 5 to 7 days before the initial dose of pemetrexed and continued until 3 weeks after the last dose of chemotherapy. Dexamethasone (4 mg administered orally or the equivalent) was administered twice daily on the day before pemetrexed, the day of treatment, and the day after chemotherapy.
Pemetrexed-related toxicities were managed with either temporary dose delays or subsequent dose reductions where appropriate. Dose delays longer than14 days prompted removal of the patient from the study protocol. Dose reductions of pemetrexed by 25% were implemented for grade 3 and 4 hematopoietic toxicities (after delaying treatment until adequate recovery of granulocyte count to 1500/mm 3 and platelet count to 100,000/mm 3 ). If more than two dose reductions (25% and then 50%) for hematopoietic toxicity were required, patients were removed from the study. A similar approach was used in the management of nonhematopoietic toxicities.
Efficacy and Safety
Patients were evaluated clinically and by laboratory assessments with every cycle of pemetrexed (every 3 weeks) to determine their tolerance and eligibility for subsequent drug administration. Baseline scans were followed by repeat imaging with computed tomography (CT) scans that were obtained every 6 weeks (two cycles) to evaluate response to treatment.
Tumor response and progression were defined by using the Response Evaluation Criteria in Solid Tumors. 9 Duration of overall response was defined as the time from when the measurement criteria were first met to achieve a complete response (CR) or partial response (PR) (whichever was recorded first) until the first date on which recurrent or progressive disease was objectively documented. Duration of stable disease was similarly defined as the date on which treatment started to the date of objective disease progression. The first evaluation for response assessment was within 6 weeks of first cycle of treatment. The final objective response rate (ORR) was determined by calculating the total number of patients who fulfilled criteria to achieve a CR or PR divided by the total number of patients treated during the study. All patients evaluable for toxicity or response were included in the denominator for this calculation.
Adverse events (AEs) were recorded and graded according to the National Cancer Institute Common Terminology Criteria version 2.0 at each study visit.
Outcomes
The primary end point of this study was the ORR (CR and PR). Secondary end points included progression-free survival (PFS), which was defined as the time from the initiation of treatment until disease progression or death; duration of response, which was defined as the time from onset of response to onset of progression; and drug-specific toxicity.
Statistical Analysis
The study was designed to test whether the ORR for pemetrexed is higher than 20% (alternative hypothesis p ¼ 0.2) versus less than 5% (null hypothesis p ¼ 0.05). The target accrual for this study was 27 patients with utilization of a two-stage design calling for premature closure of the study after 18 patients were enrolled if no evidence of response was detected in the first cohort. If one or more responses were identified among the first group, the study was to proceed with enrollment of nine additional patients. If at least four objective responses were observed, this would be considered sufficient evidence that the true ORR was at least 20%. Determination of the sample size conformed to the requirement that the maximum number of patients treated be minimized while ensuring a probability of early study termination of less than 2% if the true ORR was higher than 20%. The study was designed to generate a power greater than 80% if the true response rate was at least 20% at a significance (alpha) level of 5%. At the completion of the study, two-sided 95% confidence intervals (CIs) of the true response rate were produced by the method of Atkinson and Brown. 10 These confidence intervals take into consideration the sequential design of the study and are, as a rule, slightly wider than the usual confidence intervals used in single-stage designs. For CIs of responses within cancer type subgroup, routine CIs based on the exact binomial distribution were constructed. PFS and duration of response were calculated by the Kaplan-Meier method. Calculation of 95% CIs for medians were derived by using the Brookmeyer-Crowley method. All analyses were carried out with SAS software (version 9.3, SAS Institute Inc., Cary, NC). , and most patients were white (85%). Of the 27 patients enrolled, 16 had thymoma and the remaining 11 had TC. PS was lower than 2 for all patients enrolled (48% were had a PS of 0 and 52% had a PS of 1). All of the patients had received at least one line of chemotherapy before enrollment, with a median of two prior lines of therapy (one to five; 74% had received prior radiotherapy. Prior chemotherapy was evenly split between cisplatin-and carboplatincontaining regimens (48% each). The most common sites of metastatic involvement were the lung (59%), pleura (37%), and liver (22%).
Results

Patients
Efficacy
Of the 27 patients enrolled, 14 completed the full course of six cycles of pemetrexed. One patient was not evaluable for response because he withdrew from the study before the first evaluation. Four objective responses (two CRs and two PRs) were observed among the 18 evaluable subjects accrued in the first stage, and one additional response (a PR) was observed among the nine subjects enrolled in the second stage. Overall, there were two CRs (7.4%) and three PRs (11.1%), for an overall response rate (CR þ PR) of 19.2% (95% CI taking into account the two-stage nature of the study: 6.3-38.1). Most responses were seen in patients with thymoma, with four of the 15 patients (26.7% [95% CI: 7.8-55.1]) having an overall response, whereas only one response (a PR) was demonstrated in the 11 patients with TC (9.1% ([95% CI: 0.2-41.3]). The median duration of response for the four patients with thymoma who responded was 4 months (range 3.26-6.28 months), with the response lasting for 3.8 months in the one patient with TC who had a PR (Table 2) .
Seven patients discontinued treatment on account of disease progression during treatment (26%). Seventeen patients (65.4%) had a best response of stable disease during the study (Table 3) The median time to progression for all patients was 10.6 months (95% CI: 2.9-13.4 months). The median PFS in the two cancer types was 12.1 months in patients with thymoma (95% CI: 6.3-14.5 months) versus 2.9 months for patients with TC (95% CI: 0.6-15.0 months, p ¼ 0.4156) (Fig. 1) . With 23 deaths at the time of data cutoff in August 2015, the median overall survival (OS) was 28.7 months (95% CI: 9.8-47.2 months). The median OS among patients with thymoma was 46.4 months (95% CI: 11.3-67.5 months) versus 9.8 months in patients with TC (95% CI: 3.4-32 months, p ¼ 0.0709) (Fig. 2) . The PFS and OS times were not statistically different between the two groups. One patient with thymoma who had achieved a CR with pemetrexed remained alive at the time of data cutoff (see Table 2 ). Before enrolling in the study, she had received two lines of cisplatin-based combination therapy and a third line of treatment with erlotinib.
AEs
Treatment was generally well tolerated. Overall, the AEs reported in this study are consistent with the known toxicity profile of pemetrexed. Nine patients (33%) reported grade 3 toxicities; no grade 4 toxicities occurred in the 27 patients enrolled in the study. The most frequent grade 3 toxicities included infection (three patients), cardiopulmonary events (three patients), and gastrointestinal events (three patients). Hematologic toxicity was mild, with only one grade 3 neutropenia reported. Similarly, abnormalities in serum chemistry were infrequent and mild, with grade 2 increases in hepatic transaminase levels developing in only one patient.
Discussion
In this heavily pretreated patient population, pemetrexed, a second-generation antifolate agent, produced an objective response of 26% in patients with thymoma (four of 15). Two CRs and 2 PRs were documented, whereas there was only one PR among those with TC. The response rate of 9% in TC suggests that pemetrexed has minimal activity in this more aggressive phenotype. This is, to our knowledge, the first study to prospectively demonstrate the clinical activity of pemetrexed in thymic malignancies, and it solidifies the role of pemetrexed in the second line and beyond in advanced thymoma. As this study was being carried out, a phase I trial of pemetrexed in multiple solid malignancies that was conducted in Japan demonstrated a PR in one of the two included patients with thymoma. 11 In addition, a retrospective series of 16 patients with recurrent or metastatic thymic tumors and pemetrexed alone (n ¼ 14) or in combination (n ¼ 2) produced one PR or stable disease (n ¼ 5) among six patients with thymoma and one PR and stable disease (n ¼ 5) in 10 patients with TC. After a median follow-up of 21.2 months for thymoma and 13.5 months for TC, the median PFS (13.8 versus 6.5 months) and OS (20.1 versus 12.7 months) were also more favorable for thymoma than for TC. 12 Among all 26 evaluable patients enrolled in this study, the overall rate of response to an intravenously administered dose of 500 mg of pemetrexed every 3 weeks was 19%. Although the trial was not set up to determine a difference in response between the two subtypes of thymic malignancies, there was a remarkable difference in response to pemetrexed in the thymoma cohort versus in the population with TC (26% versus 9%). PFS was also higher with thymoma than with thymic cancer (12.1 months versus 2.9 months). At the time of initiation of the trial, it was common to lump both histologic subtypes into one category. Today, there is growing evidence that these thymic malignancies represent histologically and molecularly distinct neoplasms. [13] [14] [15] Compared with thymoma, TC is more aggressive and more likely to metastasize outside the chest cavity. 16 Genome analysis has revealed a preponderance of TC (and WHO class B3 thymoma) in a subgroup of thymic malignancies characterized by chromosomal instability (in particular, loss of 16q) and unfavorable survival outcomes. 17 In addition, CD117 (KIT proto-oncogene receptor tyrosine kinase) is frequently overexpressed in TC but not in thymoma. 18, 19 These biologic differences may explain the results of our study. Indeed, a phase II study of the combination of paclitaxel and carboplatin in recurrent thymic malignancies demonstrated an ORR of 42.9% in patients with thymoma compared with an ORR of 21.7% in the cohort with TC. 20 More recently, in a phase II study of cixutumumab, which is an insulin growth factor receptor 1 monoclonal antibody, investigators reported a 14% PR rate (5 of 37 patients) in those with thymoma whereas there was no CR or PR among the 12 patients with TC. 21 Conversely, a phase II trial of sunitinib in thymic malignancies showed a rate of PR of 26% among patients with TC compared with 6% in those with thymoma. 22 Survival numbers were not reported, but on the basis of this finding, sunitinib is recommended for patients with chemotherapy-refractory TC rather than thymoma. 23 Varied responses specifically to pemetrexed in different histologic subtypes of lung epithelial cancer are also recognized. 24, 25 Thymidylate synthase (TS), a key enzyme targeted by pemetrexed, is overexpressed in squamous cell lung cancer, which may explain why pemetrexed is less active in this histologic type than in the adenocarcinoma variant of lung cancer. 26 On the other hand, retrospective studies have been inconsistent about the role of TS expression as a predictor of response to pemetrexed in mesothelioma. [27] [28] [29] A review of 56 cases of thymic malignancies revealed TS expression in 61% of tumors. Of note, significantly higher TS expression was observed in TC than in thymoma, with higher TS expression correlated with poorer survival. 30 The relationship between TS expression and response to pemetrexed has not been established in thymic malignancies and was not examined in this study.
In this trial, pemetrexed was well tolerated, with 14 of the 27 patients completing all six scheduled cycles of therapy. There were no grade 4 AEs, and the most common grade 1 or 2 AEs were fatigue (52%) and anorexia (37%) (see Table 4 ). A major limitation of the study is the relatively small number of patients, which may account for the apparent lack of a statistically significant survival benefit with pemetrexed in thymoma versus in TC. We also did not investigate the expression of enzymes crucial for pemetrexed metabolism, so we are unable to comment on potential biomarkers of response to pemetrexed across the WHO classes of thymic malignancies captured in this trial. Another major shortcoming of the study was the prespecification to treat for a maximum of six cycles of pemetrexed (4.5 months). Of the 27 enrolled patients, 14 (52%) completed these six cycles, and it is conceivable that some of these might have tolerated, and possibly benefited from, additional cycles of treatment. Indeed, the median duration of response among the patients with thymoma and a PR or CR was 4 months, which suggests that response continued beyond treatment. We also note that our study design required an evaluation of response to treatment within 6 weeks of the start of therapy. Given the indolent nature of thymic malignancies, it could be argued that this is perhaps too short an interval, particularly as the median time to stable disease in this study was 2.76 months. Altogether, prospective clinical trials in patients with recurrent thymic malignancies are few, and most of them report response rates less than 20% (Table 5) . A response rate of approximately 25% to pemetrexed in a heavily pretreated population of patients with recurrent thymoma therefore makes this agent one of the most active to date and undergirds its role as a second-line agent after platinum-based treatment in thymoma but not in TC. More work needs to be done to determine the role of single-agent or combination regimens with pemetrexed in the first line.
Conclusion
Thymic malignancies are rare, with no established standard chemotherapy for recurrent disease. Pemetrexed is active as a second-line agent for recurrent thymoma, but information on survival outcomes is lacking. In this single-arm phase II study, pemetrexed was associated with an overall response rate of 26% in thymoma versus 9% in TC, with a median PFS of 12.1 versus 2.9 months and median OS of 46.4 versus 9.8 months, respectively.
